Frontier Bets $52m On Potential Rival To Gilead's Veklury
Executive Summary
Frontier Biotechnologies is seeking to enroll roughly 1,200 hospitalized COVID patients in an international Phase II/III clinical trial to evaluate its bofutrelvir (FB2001) in competition with Gilead’s Veklury.
You may also be interested in...
Gilead Oncology Sales Take Off As Veklury’s Come Down To Earth
As expected, the COVID-19 drug’s sales fell significantly, though it remains in frequent use among hospitalized patients. Meanwhile, oncology drug sales broke the half billion-dollar mark.
Junshi’s COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled
Unexpected protocol changes and a single-blind design for a Phase III head-to-head trial seem to have played to the advantage of Junshi’s oral derivative of Gilead’s antiviral remdesivir in COVID-19.
China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public
China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.